国际标准期刊号: 1522-4821

国际紧急心理健康和人类复原力杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 引用因子
  • 西马戈
  • 大英图书馆
  • 斯科普斯
  • 参考搜索
  • 普布隆斯
  • 大学教育资助委员会
  • 欧洲酒吧
  • 出版医学
  • ICMJE
分享此页面

抽象的

Most Common Side Effects of Clozapine and Their Management

Mohammad Masud Iqbal, Shivale Swati, Alka Aneja, Mohammad Touhid Iqbal, Esha Aneja and Sumala Haque

Clozapine is a novel, unique and oldest second generation (atypical) antipsychotic agent, first introduced in 1970s in the European market in under trade name, Leponex but has been withdrawn years in 1974 due to development of severe neutropenia (agranulocytosis) resulting in cluster of deaths. It was reintroduced in the early 1990s in United States under trade name, Clozaril by U.S. Food and drug Administration (FDA) for use in treatment resistant schizophrenia in adults and for reduction of risk of persistent suicidal ideation or aggressive behavior in schizophrenic patients. As of today, Clozapine remains the most effective antipsychotic available in reducing both positive and negative symptoms in patients with schizophrenia who fail to respond to typical antipsychotic agent, treating affective disorders, some neurological disorders, aggression, as well as psychosis in patients with dementia and parkinsonism. Most side effects associated with clozapine in general are typically benign, tolerable, and manageable.